FIGURE 3.

Knockdown of CD44 promotes the sensitivity of HCT116‐CSCs to oxaliplatin. (A) MTT assay measures lower oxaliplatin IC₅₀ values (5.28 ± 1.64 and 7.25 ± 1.81 μg/ml) against HCT116‐CSCs transfected with CD44‐siRNA relative to si‐NC (14.15 ± 2.31 μg/ml) against HCT116‐CSCs; (B) higher apoptotic rates are detected in HCT116‐CSCs transfected with CD44‐siRNA 1# than those transfected with si‐NC following exposure to oxaliplatin at concentrations of 0, 1.5 and 3.0 μg/ml; (C) flow cytometric analysis of HCT116‐CSCs transfected with CD44‐siRNA 1# and si‐NC following treatment with oxaliplatin at concentrations of 0, 1.5 and 3.0 μg/ml. *p < 0.05; **p < 0.01